{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:40:56Z","timestamp":1773132056553,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02001-y","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:39:25Z","timestamp":1773038365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences"],"prefix":"10.1186","volume":"18","author":[{"given":"Andre","family":"Mueller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Jovalekic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Chapleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Maria","family":"Bickel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emer","family":"MacSweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew W.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Koglin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"2","key":"2001_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer Disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312\u201339.","journal-title":"Cell"},{"key":"2001_CR2","doi-asserted-by":"crossref","unstructured":"Lannfelt L. A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease. Ups J Med Sci, 2023;128.","DOI":"10.48101\/ujms.v128.10316"},{"issue":"1","key":"2001_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg L, et al. Lecanemab, Aducanumab, and Gantenerumab binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s Disease. Neurotherapeutics. 2023;20(1):195\u2013206.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"2001_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21(4):306\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"2001_CR5","unstructured":"Lilly, KISUNLA (donanemab-azbt) - USPI. 2025."},{"key":"2001_CR6","unstructured":"Eisai, LEQEMBI\u00ae (lecanemab-irmb) USPI. 2025."},{"key":"2001_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14336","author":"LE Collij","year":"2024","unstructured":"Collij LE, et al. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimers Dement. 2024. https:\/\/doi.org\/10.1002\/alz.14336.","journal-title":"Alzheimers Dement"},{"key":"2001_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2025.103765","author":"L Iaccarino","year":"2025","unstructured":"Iaccarino L, et al. A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research. NeuroImage: Clinical. 2025. https:\/\/doi.org\/10.1016\/j.nicl.2025.103765.","journal-title":"NeuroImage: Clinical"},{"issue":"1","key":"2001_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"2001_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"2001_CR11","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the alzheimer\u2019s association and society for nuclear medicine and molecular imaging workgroup. Alzheimers Dement. 2025;21(1):e14338.","journal-title":"Alzheimers Dement"},{"key":"2001_CR12","doi-asserted-by":"publisher","first-page":"103949","DOI":"10.1016\/j.mcn.2024.103949","volume":"130","author":"M Johannesson","year":"2024","unstructured":"Johannesson M, et al. Lecanemab demonstrates highly selective binding to A\u03b2 protofibrils isolated from Alzheimer\u2019s disease brains. Mol Cell Neurosci. 2024;130:103949.","journal-title":"Mol Cell Neurosci"},{"issue":"1","key":"2001_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund H, et al. Sensitive ELISA detection of amyloid-\u03b2 protofibrils in biological samples. J Neurochem. 2007;103(1):334\u201345.","journal-title":"J Neurochem"},{"issue":"4","key":"2001_CR14","doi-asserted-by":"publisher","first-page":"e70184","DOI":"10.1002\/trc2.70184","volume":"11","author":"JM Kaplan","year":"2025","unstructured":"Kaplan JM, et al. Relationship between efficacy and preferential targeting of soluble A\u03b2 aggregates. Alzheimers Dement (N Y). 2025;11(4):e70184.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"5","key":"2001_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB DeMattos","year":"2012","unstructured":"DeMattos RB, et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer\u2019s disease mice. Neuron. 2012;76(5):908\u201320.","journal-title":"Neuron"},{"key":"2001_CR16","unstructured":"Lantheus Biosciences Ltd., NEURACEQ UK Summary of Product Characteristics. 2025."},{"key":"2001_CR17","doi-asserted-by":"publisher","unstructured":"Jovalekic A. et al. Experiences from clinical research and routine use of florbetaben Amyloid PET - A decade of post-authorization insights . Pharmaceuticals (Basel). 2024;17(12):1648. https:\/\/doi.org\/10.3390\/ph17121648.","DOI":"10.3390\/ph17121648"},{"key":"2001_CR18","unstructured":"Lantheus Biosciences Ltd., NEURACEQ US Prescribing Information. 2026."},{"issue":"8","key":"2001_CR19","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964\u201374.","journal-title":"Alzheimers Dement"},{"issue":"Pt 7","key":"2001_CR20","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/brain\/awt142","volume":"136","author":"R Ni","year":"2013","unstructured":"Ni R, et al. Amyloid tracers detect multiple binding sites in Alzheimer\u2019s disease brain tissue. Brain. 2013;136(Pt 7):2217\u201327.","journal-title":"Brain"},{"issue":"7","key":"2001_CR21","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.nucmedbio.2012.03.001","volume":"39","author":"MT Fodero-Tavoletti","year":"2012","unstructured":"Fodero-Tavoletti MT, et al. In vitro characterization of [18F]-florbetaben, an A\u03b2 imaging radiotracer. Nucl Med Biol. 2012;39(7):1042\u20138.","journal-title":"Nucl Med Biol"},{"issue":"18","key":"2001_CR22","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.7150\/thno.27868","volume":"8","author":"M Brendel","year":"2018","unstructured":"Brendel M, et al. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional A\u03b2 deposition rate and plaque burden at treatment initiation. Theranostics. 2018;8(18):4957\u201368.","journal-title":"Theranostics"},{"issue":"5","key":"2001_CR23","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, et al. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2025;12(5):100150.","journal-title":"J Prev Alzheimers Dis"},{"key":"2001_CR24","doi-asserted-by":"publisher","first-page":"103641","DOI":"10.1016\/j.mcn.2021.103641","volume":"114","author":"M Johannesson","year":"2021","unstructured":"Johannesson M, et al. Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer\u2019s disease. Mol Cell Neurosci. 2021;114:103641.","journal-title":"Mol Cell Neurosci"},{"issue":"10","key":"2001_CR25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaneurol.2024.2579","volume":"81","author":"L Liu","year":"2024","unstructured":"Liu L, et al. Lecanemab and vascular-amyloid deposition in brains of people with Down syndrome. JAMA Neurol. 2024;81(10):1066\u201372.","journal-title":"JAMA Neurol"},{"issue":"12","key":"2001_CR26","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.3390\/ijms22126442","volume":"22","author":"A Kouhi","year":"2021","unstructured":"Kouhi A, et al. Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives. Int J Mol Sci. 2021;22(12):6442.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2001_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12987-023-00435-2","volume":"20","author":"R Faresj\u00f6","year":"2023","unstructured":"Faresj\u00f6 R, Sehlin D, Syv\u00e4nen S. Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody. Fluids Barriers CNS. 2023;20(1):34.","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"2001_CR28","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","volume":"16","author":"N Khoury","year":"2025","unstructured":"Khoury N, et al. Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution. Nat Commun. 2025;16(1):1822.","journal-title":"Nat Commun"},{"key":"2001_CR29","unstructured":"Lantheus Germany GmbH, NEURACEQ EU Summary of Product Characteristics . 2025."},{"issue":"12","key":"2001_CR30","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41592-019-0627-0","volume":"16","author":"W Ouyang","year":"2019","unstructured":"Ouyang W, et al. ImJoy: an open-source computational platform for the deep learning era. Nat Methods. 2019;16(12):1199\u2013200.","journal-title":"Nat Methods"},{"key":"2001_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-0716-0592-9_19","volume":"2144","author":"A Christensen","year":"2020","unstructured":"Christensen A, Pike CJ. Staining and quantification of \u03b2-amyloid pathology in transgenic mouse models of Alzheimer\u2019s disease. Methods Mol Biol. 2020;2144:211\u201321.","journal-title":"Methods Mol Biol"},{"issue":"46","key":"2001_CR32","doi-asserted-by":"publisher","first-page":"32131","DOI":"10.1074\/jbc.M114.594846","volume":"289","author":"A Hatami","year":"2014","unstructured":"Hatami A, et al. Monoclonal Antibodies against A\u03b242 Fibrils Distinguish Multiple Aggregation State Polymorphisms in Vitro and in Alzheimer Disease Brain. J Biol Chem. 2014;289(46):32131\u201343.","journal-title":"J Biol Chem"},{"issue":"9","key":"2001_CR33","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/jnc.16127","volume":"168","author":"M Xiong","year":"2024","unstructured":"Xiong M, et al. Antibody engagement with amyloid-beta does not inhibit [(11)C]PiB binding for PET imaging. J Neurochem. 2024;168(9):2601\u201310.","journal-title":"J Neurochem"},{"issue":"5","key":"2001_CR34","first-page":"28","volume":"24","author":"C Brown","year":"2025","unstructured":"Brown C, Vaishnavi S. Practical recommendations for monitoring response to amyloid-targeting treatments for early Alzheimer disease. Practical Neurology (US). 2025;24(5):28\u20139.","journal-title":"Practical Neurology (US)"},{"issue":"3","key":"2001_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, et al. Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241\u20139.","journal-title":"Lancet Neurol"},{"issue":"11","key":"2001_CR36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1474-4422(25)00313-8","volume":"24","author":"BDC Boon","year":"2025","unstructured":"Boon BDC, et al. Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer\u2019s disease treated with aducanumab versus untreated: a retrospective case-control study. Lancet Neurol. 2025;24(11):931\u201344.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2001_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","volume":"144","author":"ED Plowey","year":"2022","unstructured":"Plowey ED, et al. Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol. 2022;144(1):143\u201353.","journal-title":"Acta Neuropathol"},{"key":"2001_CR38","unstructured":"Welikovitch L. Neuropathological insights into the effects of aducanumab on patients with Alzheimer\u2019s disease. CTAD. 2025."},{"issue":"1","key":"2001_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig LS, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):105.","journal-title":"Alzheimers Res Ther"},{"key":"2001_CR40","unstructured":"Sims J. The Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer\u2019s Disease: Primary Outcome Results from TRAILBLAZER-ALZ 6. CTAD. 2024."},{"key":"2001_CR41","doi-asserted-by":"crossref","unstructured":"Kulic L. Latest interim results from the brainshuttle AD study, a phase IB\/IIA study of trontinemab in people with ALZHEIMER\u2019S Disease. CTAD. 2024.","DOI":"10.1002\/alz70859_104293"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02001-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02001-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02001-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:02:12Z","timestamp":1773082932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02001-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02001-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved the use of previously collected, de-identified human brain tissue samples. Ethical approval for the use of these materials was obtained from the appropriate institutional review board, in accordance with applicable laws and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study did not involve individual participant data in any form (e.g., images, videos, or identifiable personal details).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors are employed by Lantheus or by Re:cognition Health (EM).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}